A Swedish research team has identified a method of drug and disease detection through the analysis of various compounds in exhaled breath.
Browsing: MS (LC–MS/MS, HRMS, IMS)
The themed issue on ‘emerging technologies in mass spectrometry’ has now been published online! In this issue of Bioanalysis, authors share several emerging technologies in mass spectrometry that could, in the near future, provide dramatic changes to what is considered conventional bioanalysis.
Mass spectrometry based metabolomics: a novel analytical technique for detecting metabolic syndrome?
This editorial discusses the use of mass spectrometry metabolomics as a diagnositic tool for detecting metabolic syndrome. Learn more in this article from Bioanalysis.
In this commentary, Melanie Anderson discusses the use of paper-based dried sampling technologies and how they can provide opportunities to collect biological samples in the dried state, which involves significantly smaller sample volumes than traditional sample collection approaches.
Issue 20 of Bioanalysis volume 9 is now available, including an editorial surrounding the factors which may impact PK measurements of antibody therapeutics alongside the latest methodologies, research articles and discussions of current bioanalytical challenges. Find out more about the issue here, or on the Bioanalysis webpage.
The Good Clinical Laboratory Practice accreditation will enable the company to extend its proteomic services to the analysis of clinical trial samples.
Researchers have published a new technique for the rapid and accurate identification of fentanyl, as well as a vast number of other drugs of abuse.
We talk to Zheng Oyang about his career, emerging technologies and miniature mass spectrometry as a focus for his recent work.
Post-acquisition data mining techniques for LC–MS/MS-acquired data in drug metabolite identification
This review discusses the targeted and untargeted post-acquisition data mining techniques, which facilitate the drug metabolite identification. Learn more in this article from Bioanalysis.
Development of Native and Denaturing LC-MS Methods for Characterization of Cysteine-Linked Antibody Drug Conjugates Using a Non-Toxic Mimic
Here we utilize a cysteine-linked antibody fluorophore conjugate to show how LC-MS methods may be optimized using a non-toxic ADC-mimic. The ADC-mimic was used to develop native and reduced SEC-MS conditions. The reduced mimic’s heavy and light chains, as well as its IdeS-proteolysis fragments, were used to develop reversed-phase LC-MS methods. A tryptic digest of the ADC mimic was used to develop a peptide mapping LC-MS method.